BUZZ-Caribou shares plunge as company explores sale and cancels cancer project
路透社2026/10/07 09:39October 7 - ** Caribou Biosciences (CRBU.O) shares fell 35.9% in pre-market trading to $0.72 ** Caribou Biosciences announced late Tuesday that it is exploring strategic options, including a potential sale, merger, or other transactions, to maximize shareholder value ** Caribou said it plans to halt development of its allogeneic CAR-T cell therapy programs, including vispa-cel for non-Hodgkin lymphoma and CB-011 for multiple myeloma ** Caribou also stated it will lay off employees and cut costs, with most layoffs expected to be completed by Q4 2026 ** As of June 30, the company held $113.8 millions in cash, cash equivalents, and marketable securities ** As of the previous trading day's close, the company's share price had dropped about 28% year-to-date (Note: For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them only for reader convenience. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation features.)
October 7 - ** Caribou Biosciences (CRBU.O) shares fell 35.9% in pre-market trading to $0.72
** Caribou Biosciences said on Tuesday evening that it is exploring strategic options, including a potential sale, merger, or other transactions to maximize shareholder value
** Caribou said it plans to discontinue development of its allogeneic CAR-T cell therapy programs, including vispa-cel for the treatment of non-Hodgkin lymphoma and CB-011 for the treatment of multiple myeloma
** Caribou said it will conduct layoffs and cut costs, and expects most of the layoffs to be completed by the fourth quarter of 2026
** As of June 30, the company held $113.8 million in cash, cash equivalents, and marketable securities
** As of the close of the previous trading session, the company’s shares had fallen about 28% year-to-date
(To better serve non-English native speakers, Reuters provides automated translations of its reports into several other languages. Because machine translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of these automated translations, which are provided for the convenience of readers only. Reuters assumes no responsibility for any damage or loss resulting from the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitmine CEO Tom Lee Says the Cryptocurrency Market is at the Beginning of a Super Cycle! Here Are the Details
BUZZ - UBS downgrades Besi to 'Sell' due to risks from hybrid bonding adoption; share price drops accordingly
Key update on share price in the first point; update on the performance of European peer stocks in the eighth point. October 7th - BE Semiconductor Industries (BESI.AS) shares fell by about 9.5% after UBS downgraded the Dutch chip equipment manufacturer’s rating from “Buy” to “Sell” and slashed its target price by 57% to 159 euros. UBS stated that expectations for demand for chip packaging technology “hybrid bonding”—which is at the core of Besi’s investment thesis—“have not materialized as expected.” According to UBS, adoption of hybrid bonding technology in high-bandwidth memory will slow because AI accelerator clients currently prioritize capacity expansion over performance improvements. UBS expects that by 2028, hybrid bonding technology will account for 10% of equipment demand, whereas market consensus suggests this proportion is around 50%. The bank projects that Besi’s hybrid bonding (HB) revenue in 2027-28 will be 50-60% lower than market expectations, and that demand from co-packaged optics, AI accelerators, and PC processors is unlikely to fill that gap. UBS stated that existing capacity at TSMC (2330.TW) and Intel (INTC.O) is already sufficient to support “substantial shipment volumes” and unless adoption rates exceed expectations, the upside is limited. Besi’s share price extended Tuesday’s downturn, after Bank of America Global Research also downgraded the stock based on similar concerns, with shares closing down 5.4% on Tuesday (link). In other European semiconductor stocks: ASML (ASML.AS) declined 2.3%, ASM International (ASMI.AS) dropped 5.3%, Infineon (IFXGn.DE) fell 5.8%, X-Fab (XFAB.PA) lost 5.8%, Soitec (SOIT.PA) was down 4.1%, STMicroelectronics (STMPA.PA) dropped 3.8%, Aixtron (AIXGn.DE) fell 2.7%, and ams-OSRAM (AMS2.VI) fell 3.6%. (Note: For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Because automated translations may be incorrect or may not include the intended context, Reuters does not guarantee the accuracy of translated texts and provides them solely for reader convenience. Reuters assumes no responsibility for any damage or loss caused by using automated translation features.)
Temasek Chief Investment Officer warns: AI trading reversal is the biggest market risk, turbulence may occur in 2027
Temasek's CIO stated that AI-driven trading reversals represent the greatest market risk, with possible turbulence in 2027; however, he remains optimistic in the long term and plans to raise public AI exposure to 70%—75%.
Intel Confirms Advancement of Musk's "Terafab" Chip Plan Amid Stock Price Pressure
Intel CEO Pat Gelsinger stated that the company will continue to participate in Elon Musk's Terafab project. Previously, Musk revealed ongoing discussions with TSMC about potential collaboration, which raised market concerns over Intel's position in the project. As a result, Intel's stock price once dropped by 3.9%.
Crypto prices
More
